Answers are grounded in this paper and cite their sources.
Background Type 2 diabetes mellitus (T2DM) has been increasingly associated with neurocognitive and neurodegenerative changes, but the underlying mechanisms and the potential of circulating biomarkers for early detection remain unclear. We measured serum levels of neurofilament light chain (NfL), carbonic anhydrase II (CA-II), and amyloid-beta 42 (Aβ42) and examined their associations with diabetes status and screening-defined cognitive status. Methods This cross-sectional study included 90 individuals with T2DM and 90 non-diabetic controls. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), and blood samples were collected to measure NfL, Aβ42, and CA-II concentrations. We compared cognitive scores, biomarker concentrations, and clinical characteristics between the groups. Participants were also classified according to their cognitive status. Age-adjusted analysis of covariance (ANCOVA) was then used to examine the independent and combined associations of diabetes and cognitive status with biomarker levels. Results The study included 180 participants (90 with diabetes and 90 without diabetes). Compared with non-diabetic participants, those with diabetes had significantly higher serum neurofilament light chain (NfL) levels (27.85 ± 12.88 vs. 22.53 ± 8.34 pg/mL, P = 0.001) and lower amyloid-beta 42 (Aβ42) levels (26.86 ± 13.29 vs. 34.21 ± 17.11 pg/mL, P = 0.002), whereas carbonic anhydrase II (CA-II) levels did not differ significantly. Participants with cognitive impairment (MoCA < 26) had significantly lower Aβ42 and higher CA-II levels than those with normal cognition (both P < 0.001), while NfL levels were comparable between cognitive groups ( P = 0.462). In age-adjusted analyses, diabetes was significantly associated with higher NfL levels ( P = 0.001), whereas cognitive status and the diabetes–cognitive status interaction were not significant. Both diabetes and cognitive status were significantly associated with Aβ42 levels (both P < 0.001), with a significant interaction between them ( P < 0.001). For CA-II, cognitive status ( P = 0.015) and its interaction with diabetes ( P = 0.001) were significant, whereas the main effect of diabetes was not ( P = 0.724). The highest adjusted CA-II levels were observed in participants with both diabetes and cognitive impairment. Conclusion Circulating NfL, Aβ42, and CA-II showed different patterns of association with diabetes and cognitive status. NfL was associated with diabetes irrespective of cognitive status, which may reflect diabetes-related neuroaxonal injury. Aβ42 was associated with both diabetes and cognitive status, with evidence of an interaction between the two. CA-II was not associated with diabetes alone but was associated with cognitive impairment, particularly among participants with T2DM. These findings suggest that a multi-marker approach may help characterize neurocognitive changes in T2DM. Longitudinal studies are needed to determine whether these biomarkers predict cognitive decline and to define their clinical utility.
No takes yet. Share an insight, caveat, or question.
Abbasihormozi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: